Ligand Pharmaceuticals Incorporated (LGND)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 164 | 242 | 196 | 131 | 167 | 268 | 291 | 290 |
| Operating profit | $m | 47 | 101 | ||||||
| Net profit | $m | -3 | 57 | -33 | 52 | -4 | 124 | 197 | 189 |
| EPS reported | $ | 6.13 | 9.35 | ||||||
| Operating cashflow per share | $ | 2.55 | 6.56 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | 2.53 | 6.55 | ||||||
| Free cash flow | $m | 49 | 131 | ||||||
| Net debt | $m | -287 | -231 | ||||||
| Book value equity | $m | 1,017 | 968 | ||||||
| Book value per share | $ | 50.12 | 44.31 | ||||||
| Number of shares | m | 20.29 | 21.84 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 30.84 | 33.59 | ||||||
| P/B LTM | x | 3.59 | 3.78 | ||||||
| P/S LTM | x | 13.64 | 12.58 | ||||||
| P/FCF LTM | x | 74.76 | 27.83 | ||||||
| EV/EBITDA LTM | x | 20.41 | 14.37 | ||||||
| EV/Sales LTM | x | 14.67 | 20.75 | ||||||
| Earnings Yield LTM | % | +3.24% | +2.98% | ||||||
| FCF Yield | % | +1.34% | +3.59% | ||||||
| Quality | |||||||||
| ROE | % | +12.23% | +20.06% | ||||||
| ROIC | % | +2.42% | +3.91% | ||||||
| Operating margin | % | +17.61% | +34.74% | ||||||
| Gross margin | % | +97.54% | +98.58% | ||||||
| FCF/Sales | % | +18.24% | +45.21% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +60.40% | +73.84% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -36.82% | +69.71% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.11 | 0.12 | ||||||
| Net Debt/EBITDA | x | 1.43 | 0.46 | ||||||
| EBIT/Net interest | x | 10.01 | 16.31 | ||||||
| Net debt/market cap | % | +12.20% | +19.08% | ||||||
| Net debt/Equity | x | -0.28 | -0.24 | ||||||
| Gross debt/equity | x | 0.44 | 1.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ligand Pharmaceuticals Incorporated (LGND)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free